Acute exacerbations of asthma, also called acute severe asthma, is an ongoing asthma episode in which asthma symptoms do not adequately respond to initial bronchodilator or corticosteroid therapy. Palatin has an IND application with an approved clinical trial protocol for a proof-of-concept human trial for asthma using a subcutaneously administered formulation of PL-3994. Palatin has also commenced development of an inhalation formulation of PL-3994.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.
SOURCE Palatin Technologies, Inc.